ALAB Stock Analysis: Astera Labs | NASDAQ
Semiconductors | NASDAQ, USA | Market Cap: 69.664m USD | 12M Return: 382.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.36B
Qual. Beats: 4
Rev. Trend: 99.3%
Qual. Beats: 5
Warnings
Tailwinds
Seasonality 2.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Astera Labs, Inc. (NASDAQ: ALAB) designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure, operating primarily in the United States and Taiwan. The companys product portfolio centers on an intelligent connectivity platform featuring high-speed, mixed-signal connectivity products, supported by its COSMOS software suite for fleet management and system optimization. Its hardware offerings include PCIe/CXL smart DSP retimers, ethernet smart cable modules, CXL memory connectivity controllers, and smart fabric switches. Astera Labs serves hyperscalers (large-scale cloud and internet operators) and system original equipment manufacturers (OEMs). The company was incorporated in 2017, is headquartered in San Jose, California, and went public in March 2024.
The company sits within the Information Technology sectors Semiconductors sub-industry, focusing on a specialized niche of high-speed data interconnect components that enable data movement between processors, memory, and accelerators in modern data centers. Its product roadmap is closely tied to industry-standard interconnect protocols such as PCIe and CXL, which are widely used to link CPUs, GPUs, and memory subsystems in server and AI infrastructure.
- AI infrastructure buildout boosts retimer and fabric switch revenue
- Gross margins face pressure from Broadcom and Marvell competition
- Hyperscaler customer concentration creates revenue volatility risk
| Net Income: 267.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 11.02 > 1.0 |
| NWC/Revenue: 128.6% < 20% (prev 203.6%; Δ -74.98% < -1%) |
| CFO/TA 0.23 > 3% & CFO 383.4m > Net Income 267.6m |
| Net Debt (-1.15b) to EBITDA (279.3m): -4.10 < 3 |
| Current Ratio: 11.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (181.2m) vs 12m ago 1.71% < -2% |
| Gross Margin: 75.99% > 18% (prev 75.76%; Δ 0.23% > 0.5%) |
| Asset Turnover: 72.02% > 50% (prev 43.73%; Δ 28.30% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.78 (Total Current Assets 1.41b - Total Current Liabilities 125.0m) / Total Assets 1.66b |
| B: 0.05 (Retained Earnings 90.6m / Total Assets 1.66b) |
| C: 0.19 (EBIT TTM 269.9m / Avg Total Assets 1.39b) |
| D: 9.04 (Book Value of Equity 1.49b / Total Liabilities 165.3m) |
| Altman-Z'' = 16.07 = AAA |
| DSRI: 0.95 (Receivables 134.8m/69.8m, Revenue 1.00b/490.5m) |
| GMI: 1.00 (GM 75.76% / 75.99%) |
| AQI: 15.75 (AQ_t 0.09 / AQ_t-1 0.01) |
| SGI: 2.04 (Revenue 1.00b / 490.5m) |
| TATA: -0.07 (NI 267.6m - CFO 383.4m) / TA 1.66b) |
| Beneish M = 6.41 (Cap -4..+1) = D |
As of July 07, 2026, the stock is trading at USD 432.74 with a total of 4,114,168 shares traded. Over the past week, the price has changed by +10.47%, over one month by +24.95%, over three months by +266.76% and over the past year by +382.86%.
Current recommended Stop Loss: 340.00 (which is 21.4% or 2.3 ATR below the current price).
Astera Labs has received a consensus analysts rating of 4.47. Therefore, it is recommended to buy ALAB.
- StrongBuy: 9
- Buy: 7
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 272.5 | -37% |
P/E Trailing = 278.3699
P/E Forward = 147.0588
P/S = 69.5632
P/B = 49.4347
Revenue TTM = 1.00b USD
EBIT TTM = 269.9m USD
EBITDA TTM = 279.3m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 39.3m USD (from shortLongTermDebtTotal, last fiscal year) + Leases 4.15m
Net Debt = -1.15b USD (calculated: Debt 39.3m - CCE 1.18b)
Enterprise Value = 68.5b USD (69.7b + Debt 39.3m - CCE 1.18b)
Interest Coverage Ratio = unknown (Ebit TTM 269.9m / Interest Expense TTM 0.0)
EV/FCF = 199.9x (Enterprise Value 68.5b / FCF TTM 342.8m)
FCF Yield = 0.50% (FCF TTM 342.8m / Enterprise Value 68.5b)
FCF Margin = 34.23% (FCF TTM 342.8m / Revenue TTM 1.00b)
Net Margin = 26.72% (Net Income TTM 267.6m / Revenue TTM 1.00b)
Gross Margin = 75.99% ((Revenue TTM 1.00b - Cost of Revenue TTM 240.5m) / Revenue TTM)
Gross Margin QoQ = 76.26% (prev 75.57%)
Tobins Q-Ratio = 41.30 (Enterprise Value 68.5b / Total Assets 1.66b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 39.3m)
Taxrate = 0.82% (2.23m / 269.9m)
NOPAT = 267.6m (EBIT 269.9m * (1 - 0.82%))
Current Ratio = 11.30 (Total Current Assets 1.41b / Total Current Liabilities 125.0m)
Debt / Equity = 0.03 (Debt 39.3m / totalStockholderEquity, last quarter 1.49b)
Debt / EBITDA = -4.10 (Net Debt -1.15b / EBITDA 279.3m)
Debt / FCF = -3.34 (Net Debt -1.15b / FCF TTM 342.8m)
Total Stockholder Equity = 1.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 19.25% (Net Income 267.6m / Total Assets 1.66b)
RoE = 20.33% (Net Income TTM 267.6m / Total Stockholder Equity 1.32b)
RoCE = 17.59% (EBIT 269.9m / Capital Employed (Total Assets 1.66b - Current Liab 125.0m))
RoIC = 18.03% (NOPAT 267.6m / Invested Capital 1.48b)
WACC = 17.58% (E(69.7b)/V(69.7b) * Re(17.59%) + D(39.3m)/V(69.7b) * Rd(0.0%) * (1-Tc(0.01)))
Discount Rate = 17.59% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 7.95%
[DCF] Terminal Value 53.74% ; FCFF base≈249.0m ; Y1≈285.4m ; Y5≈420.0m
[DCF] Fair Price = 20.47 (EV 2.36b - Net Debt -1.15b = Equity 3.51b / Shares 171.4m; r=17.58% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.27 | # QB: 4
Revenue Correlation: 99.25 | Revenue CAGR: 172.1% | SUE: 2.18 | # QB: 5
EPS current Quarter (2026-06-30): EPS=0.69 | Chg30d=+0.00% | Revisions=+87% | Analysts=22
EPS next Quarter (2026-09-30): EPS=0.79 | Chg30d=+0.36% | Revisions=+25% | Analysts=21
EPS current Year (2026-12-31): EPS=3.01 | Chg30d=+0.22% | Revisions=+88% | GrowthEPS=+63.6% | GrowthRev=+81.7%
EPS next Year (2027-12-31): EPS=4.31 | Chg30d=+2.39% | Revisions=+88% | GrowthEPS=+43.1% | GrowthRev=+43.3%
[Analyst] Revisions Ratio: +96% (up=66, down=0)